Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lexicon Pharmaceuticals Inc LXRX

Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure... see more

Recent & Breaking News (NDAQ:LXRX)

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

GlobeNewswire 3 days ago

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

GlobeNewswire May 14, 2024

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

GlobeNewswire May 9, 2024

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 2, 2024

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

GlobeNewswire April 29, 2024

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

GlobeNewswire April 29, 2024

Lexicon Pharmaceuticals to Host 2024 Investor Day

GlobeNewswire April 18, 2024

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

GlobeNewswire March 25, 2024

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire March 12, 2024

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire March 11, 2024

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

GlobeNewswire March 11, 2024

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

GlobeNewswire March 11, 2024

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2024

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

GlobeNewswire December 21, 2023

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

GlobeNewswire November 30, 2023

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 22, 2023

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

GlobeNewswire November 12, 2023

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 10, 2023

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 8, 2023